Truist Financial Corp decreased its stake in shares of Danaher Corporation (NYSE:DHR – Free Report) by 7.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 326,593 shares of the conglomerate’s stock after selling 27,679 shares during the period. Truist Financial Corp’s holdings in Danaher were worth $64,750,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in the stock. Sivia Capital Partners LLC boosted its holdings in Danaher by 6.3% during the second quarter. Sivia Capital Partners LLC now owns 2,009 shares of the conglomerate’s stock worth $397,000 after purchasing an additional 119 shares during the last quarter. Janney Montgomery Scott LLC lifted its position in Danaher by 7.7% during the 2nd quarter. Janney Montgomery Scott LLC now owns 199,045 shares of the conglomerate’s stock worth $39,319,000 after buying an additional 14,277 shares in the last quarter. Capital Investment Advisors LLC boosted its stake in shares of Danaher by 1.2% during the 2nd quarter. Capital Investment Advisors LLC now owns 7,352 shares of the conglomerate’s stock worth $1,452,000 after buying an additional 85 shares during the last quarter. Trivium Point Advisory LLC grew its holdings in shares of Danaher by 35.4% in the 2nd quarter. Trivium Point Advisory LLC now owns 2,242 shares of the conglomerate’s stock valued at $443,000 after acquiring an additional 586 shares in the last quarter. Finally, Liberty Capital Management Inc. grew its holdings in shares of Danaher by 3.3% in the 2nd quarter. Liberty Capital Management Inc. now owns 35,300 shares of the conglomerate’s stock valued at $6,973,000 after acquiring an additional 1,128 shares in the last quarter. 79.05% of the stock is owned by institutional investors.
Insider Transactions at Danaher
In related news, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $210.42, for a total value of $1,088,713.08. Following the completion of the sale, the senior vice president directly owned 2,625 shares in the company, valued at $552,352.50. The trade was a 66.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Teri List sold 3,298 shares of the stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $226.50, for a total value of $746,997.00. Following the transaction, the director owned 20,762 shares in the company, valued at $4,702,593. The trade was a 13.71% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 30,248 shares of company stock worth $6,609,663 over the last quarter. Company insiders own 11.20% of the company’s stock.
Wall Street Analysts Forecast Growth
View Our Latest Stock Analysis on Danaher
Trending Headlines about Danaher
Here are the key news stories impacting Danaher this week:
- Positive Sentiment: Q4 beat — Danaher reported $2.23 EPS (above consensus) and $6.84B revenue, with revenue up ~4.5% year?over?year, showing underlying operational strength. Danaher Reports Fourth Quarter and Full Year 2025 Results
- Positive Sentiment: Bioprocessing and diagnostics led growth — management flagged life?sciences/bioprocessing strength as a driver and analysts point to upside from bioprocessing exposure. Danaher Q4 Earnings Beat Estimates, Life Sciences Sales Up Y/Y
- Neutral Sentiment: FY?2026 guidance came in essentially in?line (EPS 8.350–8.500 vs. consensus ~8.42); management described a gradual improvement in end?market conditions rather than an immediate acceleration. Danaher forecasts 2026 profit in line with estimates on pharma spending recovery
- Neutral Sentiment: Management emphasized cash strength and a balanced result, which supports financial flexibility but did not materially change capital allocation or upside expectations. Danaher Earnings Call: Cash Strength Amid Cautious Outlook
- Negative Sentiment: Shares sold off despite the beat — investors likely disappointed by the cautious tone and guidance that was only inline, leading to profit?taking after a recent run toward the 1?year high; rich valuation (PE ~46) magnifies sensitivity to any lack of upside. Danaher Expects Gradual Improvement In End-Market Conditions
Danaher Trading Down 5.0%
Shares of Danaher stock opened at $224.00 on Thursday. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.52 and a quick ratio of 1.10. The business has a fifty day simple moving average of $230.83 and a two-hundred day simple moving average of $213.77. Danaher Corporation has a 1 year low of $171.00 and a 1 year high of $242.80. The company has a market capitalization of $158.22 billion, a price-to-earnings ratio of 46.19, a P/E/G ratio of 3.59 and a beta of 0.89.
Danaher (NYSE:DHR – Get Free Report) last issued its quarterly earnings data on Wednesday, January 28th. The conglomerate reported $2.23 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.09. The company had revenue of $6.84 billion for the quarter, compared to analyst estimates of $6.79 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The company’s revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.14 earnings per share. Danaher has set its FY 2026 guidance at 8.350-8.500 EPS. Research analysts forecast that Danaher Corporation will post 7.63 EPS for the current year.
Danaher Dividend Announcement
The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Friday, December 26th will be given a dividend of $0.32 per share. The ex-dividend date is Friday, December 26th. This represents a $1.28 annualized dividend and a yield of 0.6%. Danaher’s dividend payout ratio (DPR) is 26.39%.
Danaher Company Profile
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Recommended Stories
- Five stocks we like better than Danaher
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- NEW LAW: Congress Approves Setup For Digital Dollar?
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- A U.S. “birthright” claim worth trillions – activated quietly
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
